https://www.reuters.com/world/us/novavax-files-us-authorization-covid-19-vaccine-2022-01-31/
The filing is based on data provided to the U.S. Food and Drug Administration last month and results of two late-stage trials in the United States, Mexico and the UK that showed the protein-based vaccine had an overall efficacy of about 90%, the company said.